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ABSTRACT 
The majority of naturally occurring proteins are modified in some manner, with many 
biological systems requiring these modifications in order to function properly. 
Acylation is one such type of modification. For example, the neuropeptide ghrelin, 
which plays a critical role in appetite stimulation, is octanoylated on its ser-3 residue. 
Many proteins are palmitoylated at one or more cysteine residues, with the lipid moiety 
essential for membrane binding. It is likely that many biological systems rely on protein 
acylations, and it would be beneficial to develop techniques that allow a facile detection 
of naturally occurring acylations. 
Synthetically acylated peptides and proteins (a class of monodisperse polymer) have 
many potential uses. Synthetically acylated peptides and proteins are being developed 
for use as therapeutic agents and also as chemical standards. Synthetically acylated 
peptides, for example, have the potential for use as vaccines for diseases such as 
hepatitis and HIV. The ability to successfully characterise these types of semi-synthetic 
molecules is imperative in their development process. In this work, mass spectrometry 
is explored as a means of analysing acylated peptides and proteins. 
A number of synthetically acylated peptides were examined using a range of mass 
spectrometry techniques in order to identify characteristic fragmentations. Acylated 
peptides were fragmented using electrospray ionisation or matrix-assisted laser 
desorption/ionisation combined with collisionally induced dissociation tandem mass 
spectrometry, and also using matrix-assisted laser desorption/ionisation post source 
decay mass spectrometry. Acylated peptides were observed to fragment in a similar 
manner to their unacylated counterparts, with the degree of fragmentation observed 
dependant on the length of the acyl chain (i.e. higher collision energies were required to 
 xv
illicit the same degree of fragmentation with increasing chain length). The presence of 
an acylation on an N-terminal amino acid allowed the formation of a b1 product ion, not 
normally observed in the spectrum of unmodified peptides. A number of useful marker 
ions for acylation at serine, tyrosine and cysteine residues were observed, including, 
acyl carbenium ions and acylated immonium ions. The neutral loss of the acyl moiety 
was also commonly observed. The tandem mass spectrometry conditions required to 
produce marker ions were explored. 
Two lipopeptides, synthesised as by-products in the production of N-terminally acylated 
HIV protein Nef1-6 (acyl-GGKWSK), were characterised. These lipopeptides were 
found to be twelve residues long, with an unusual ether-linked kynurenine at position 
seven, and contained either a stearoyl or oleoyl moiety at their N-terminal glycine 
residues (ste/ole-GGKWSK-O-kyn-SKWSK). The successful characterisation of these 
molecules has allowed continued investigations into their use as immunological agents. 
A range of novel monodisperse polymers, acylated at their lysine residues, were 
analysed intact or subsequent to enzymatic digestion, using high performance liquid 
chromatography and tandem mass spectrometry. Analogous tandem mass spectra were 
observed irrespective of the acylating agent, however, chromatographic elution times 
were found to be dependant on the identity of the acyl moiety. Acylated lysine 
carbenium ions were observed in the tandem mass spectra, 17 u lower in mass than the 
calculated value for an acylated lysine immonium ion.  
This work demonstrates the ability of mass spectrometry to enable the characterisation 
of a wide range of acylated peptides and proteins. The use of a variety of mass 
spectrometry and commonly employed analysis techniques (such as enzymatic 





I would first and foremost like to thank my family. My husband, Santiago for his 
patience and my three children, James, Emily and Annabelle for being themselves. 
 
I thank my initial supervisor Margaret Sheil, who instilled in me a passion for mass 
spectrometry; the late Larry Hick, who showed me the ropes of an electrospray 
quadrupole and John Korth for valuable instruction on MALDI-TOF. 
 
I would like to thank all those in the following groups and institutions who have helped 
me during the duration of my PhD studies: 
 
- University of Wollongong, School of Chemistry and School of Biological 
Sciences. In particular, the Mass Spectrometry Group. 
 
- Pfizer, Ann Arbor, Michigan. Where I fine-tuned my LC/MS skills. 
 
- Boston University, Mass Spectrometry Resource. Cathy Costello kindly allowed 
me to join her group, with the project of developing mass spectrometry for the 
analysis of acylated peptides. 
 
- Collaborators at Brigham and Women’s Hospital, Boston. D. Branch Moody and 
his group who asked me to sequence an interesting pair of acylated peptides. 
 
- Collaborators at Harvard University, Boston. George Whitesides group. In 
particular, Jerry Yang and Katie Gudiksen, who had prepared a range of acylated 
proteins.  
 
Thanks go to my friend Sarah Cook for proofreading my thesis and to my Mum for 
proofreading the reference list. 
 
And final thanks go to Will Price, who supported me through the final hurdles of 
preparing this thesis. 
 
